Efficacy and safety of human intravenous immunoglobulin 5% (Ig VENA) in pediatric patients affected by primary immunodeficiency

Int J Immunopathol Pharmacol. 2020 Jan-Dec:34:2058738420943006. doi: 10.1177/2058738420943006.

Abstract

Patients affected by primary immunodeficiencies are characterized for high susceptibility for severe infections. Our data demonstrate Kedrion 5% intravenous immunoglobulin G (IVIg) treatment effective and safe as replacement therapy for children and adolescents affected by primary immunodeficiency. The particularities of our study are the selection of a long period of follow-up (71 patient-years of follow-up), and to the best of our knowledge, our study is one of few that assesses the safety and efficacy of intravenous immunoglobulin treatment of primary immunodeficiency specifically in a pediatric population.

Keywords: IVIg; antibody defects; efficacy; immunoglobulin; infections; primary immunodeficiency; safety.

Publication types

  • Observational Study

MeSH terms

  • Administration, Intravenous
  • Adolescent
  • Age Factors
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Immunocompromised Host
  • Immunoglobulins, Intravenous / administration & dosage*
  • Immunoglobulins, Intravenous / adverse effects
  • Immunologic Factors / administration & dosage*
  • Immunologic Factors / adverse effects
  • Infant
  • Infant, Newborn
  • Male
  • Patient Safety
  • Primary Immunodeficiency Diseases / diagnosis
  • Primary Immunodeficiency Diseases / drug therapy*
  • Primary Immunodeficiency Diseases / immunology
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Substances

  • Immunoglobulins, Intravenous
  • Immunologic Factors